MDMA-Assisted Psychotherapy Expanded Access program has been accepted by the FDA! The FDA will be allowing only a limited number of patients (less than 50 in the entire country) to enroll outside of the phase III trial. This is an incredible moment in the approval process.
Read MoreSleeping Octopus Assembly on Psychedelics is Sept 27-29th in Pittsburgh. It is a fun and relaxed conference, a nice mix of healthcare workers, psychedelic scientists, artists, philosophers, and enthusiasts. The lineup includes visionaries such as Rick Doblin, the founder of MAPS, and we are honored to announce that Hannah McLane and Michelle Joy will be giving a talk on ethics and access to innovative therapies for trauma. They will also be joining Rick Doblin and a few others for a panel discussion on Saturday afternoon. We hope to see you there!
Read MoreAs many of you know, the Multidisciplinary Association for Psychedelic Studies (MAPS) is working toward FDA approval for patients with post-traumatic stress disorder (PTSD) to be treated with MDMA through Expanded Access. MDMA has already passed Phase I (safety and dosage) and Phase II (efficacy and side effects) clinical research trials. In Phase III, they are further evaluating efficacy and safety.
Read More
